

GENERAL TOXICOLOGY

Sub-chronic 90-day repeated dose toxicity study
(OECD 408, 409, 411, CPMP/SWP/1042/99 Rev.1 Corr.)

The **sub-chronic (90-day) repeated dose toxicity study** provides information on the possible health hazards associated with repeated exposure to a test substance over a prolonged period following administration.

Properly conducted sub-chronic tests should provide a fair estimation of a no-effect level.

▶ **STUDY DURATION:**

- 32 weeks (90-day of treatment + 28-day recovery period - optional)

▶ **PRELIMINARY STUDY - OPTIONAL:**

- Acute or repeated dose 28-day toxicity tests

▶ **READOUTS / ENDPOINTS:**

- Body weight and food consumption monitoring
- Detailed observations
- Clinical signs and mortality
- Clinical pathology such as haematology, biochemistry and coagulation
- Sensory reactivity, grip strength and motor activity
- Ophthalmic exam
- Detailed necropsy and histopathology
- Hormonal measurements





OUR MISSION

VectorB2B aims to enable the discovery and development of new therapies, by offering a range of comprehensive services and expertise to clients in the biotech, pharmaceutical, and academic sector. We earn our clients' trust by offering the best services, tailored to your specific needs.

WHY US?

We offer a low-risk “one-stop shop” for large- or small-scale projects, made possible by the depth of experience and the expertise of VectorB2B scientific team. VectorB2B will deliver high-quality custom or standard drug discovery solutions on time and budget.

CONTACT US

Our team is looking forward to meeting you and discussing the most efficient way to achieve your program goals



acustodio@vectorb2b.com



www.vectorb2b.com



VectorB2B-Drug Development



VECTOR ^{B2B}

DRIVING FORCE
in drug developing services